Assyro AI
US FDAUnited StatesCRLComplete Response Letter

Complete Response Letter NDA 505b1 219029 (May 29, 2025)

Issued May 29, 2025

Issued

May 29, 2025

Application

NDA 505b1 • 219029

Review center

CDER

Stage

Final Decision

Letter type

Complete Response Letter

Requires resubmission addressing deficiencies.

Summary

This section serves as a representation of an electronically signed record, detailing the electronic signature and associated metadata such as the signing date, time, and a reference ID.

Key points

  • No explicit regulatory obligations or requirements are stated within this descriptive text.
  • Respond to agency requests within the prescribed timeline.

Cited reasons

  • Agency deficiencies
  • No specific deficiencies could be extracted from the provided truncated letter text. The letter indicates a complete response, suggesting the application is not ready for approval.

Recommended actions

  • No explicit regulatory obligations or requirements are stated within this descriptive text.

Deficiency summary

No specific deficiencies could be extracted from the provided truncated letter text. The letter indicates a complete response, suggesting the application is not ready for approval.

Findings

Agency deficiencies

Severity: major

Respond to agency requests within the prescribed timeline.

Regulatory context

Submission stage
final decision
Regulatory pathway
NDA

Impact

Impact score
0.75
Estimated delay
180 days
Estimated rework cost
$0
Subsequent action
resubmission

Strategic insights

The provided letter text is too truncated to identify specific themes or issues leading to the complete response. The decision is a complete response, indicating the application is not approvable in its current form.

Regulatory change impact: Pending sponsor mitigation plan

Approval likelihood after response: 25%

Document viewer

Read the FDA letter and send context to the co-pilot at any time.

Loading document viewer…